INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Advancements of Cancer Treatments and Cure

Priyanka Tadkase*[1], Shital Bhimewar[2], Pallavi Bawanthade[3], Fiza Firoz Karvinkar[4], Dhanashri Chelmelwar[5]

[1,3,4]*Raigad College of Pharmacy.*
[2] *S.S.S Indira College of Pharmacy.*
[5]*Kadhar College of Pharmacy.*

ARTICLE INFO

Published: 13 Feb. 2025
Keywords:
Cancer, immunotherapy, CAR-T-cell therapy, monoclonal antibody, mRNA vaccine.
DOI:
10.5281/zenodo.14864223

ABSTRACT

Cancer is a disease characterized by the unregulated growth and replication of cells. Advances in early detection have led to a reduction in death rates for various cancer types. Nonetheless, cancer remains the second leading cause of death globally, trailing only cardiovascular diseases. Consequently, cancer research is primarily aimed at discovering more effective treatments to lower cancer mortality. A deeper understanding of the molecular mechanisms within cancer cells has facilitated significant advances in treatment approaches. The key focus of this research is to create therapies that achieve high response rates while minimizing side effects. In this setting, immunotherapies have heralded a new era in cancer treatment. This review provides insights into the future of next-generation therapeutic methods, emphasizing preferred immunotherapy optionsuse.

INTRODUCTION

Cancer is characterized by the uncontrolled proliferation of cells, which exhibit distinct traits compared to normal cells. These traits include the ability to sustain proliferative signaling, resist growth-inhibiting signals, evade cell death, replicate indefinitely, promote blood vessel formation, encourage invasion and metastasis, alter their metabolism, and avoid immune detection. Cancer cells, due to genetic mutations, bypass the normal regulatory mechanisms of the cell cycle and exclude themselves from apoptosis. Environmental factors play a critical role in cancer development alongside genetic changes. These factors encompass physical carcinogens like ionizing and ultraviolet radiation; chemical agents such as tobacco, alcohol, and asbestos; and dietary exposure to substances like arsenic and aflatoxin. Biological agents, including infections from specific bacteria, viruses, or parasites, also

***Corresponding Author:** Priyanka Tadkase
Address: Raigad College of Pharmacy.
Email ✉: bhagyashreeatish7@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

contribute to cancer-related deaths, with approximately one-third of these cases linked to smoking, alcohol abuse, obesity, poor diet, and lack of exercise. Despite the availability of early detection methods and advanced treatments, cancer remains a significant global health challenge, marked by high rates of incidence and mortality. The World Health Organization estimates that approximately 10 million people died from cancer in 2020, representing one in six deaths. The most frequently diagnosed cancers among women include breast, colorectal, lung, cervical, and thyroid cancers, while for men, the most prevalent are lung, prostate, colorectal, stomach, and liver cancers. The leading cancer types in terms of new cases in 2020 were breast, lung, colon and rectum, prostate, skin, and stomach cancers. Meanwhile, lung, colorectal, and stomach cancers, alongside liver and breast cancers, accounted for the majority of cancer-related deaths that year. While many cancer types have seen a decline in mortality rates due to effective treatments, the majority of cancer research continues to concentrate on developing improved therapies. As our understanding of the molecular mechanisms of cancer deepens, treatment approaches have evolved. The rising number of cancer patients presents significant challenges worldwide. Nevertheless, efforts to identify treatments that offer high response rates with reduced side effects persist. Various cancer treatments currently employed include surgery, radio- or chemotherapy, hormone therapy, photodynamic therapy, targeted therapy, stem cell transplantation, hyperthermia, and immunotherapy. These modalities are often combined to counteract the cancer's resistance mechanisms. This review anticipates the future of next-generation cancer therapeutics by examining ongoing research and discussing key factors that could shape both national and international strategies.

Immunotherapies

Immunotherapy has emerged as a leading advanced treatment strategy within various therapeutic options for both hematological and solid tumors. Immunotherapy utilizes the patient's immune system to combat cancer, promoting more precise and effective treatment alternatives. Compared to traditional chemotherapy, immunotherapy generally involves fewer side effects, making it a promising option for diverse malignancies. Current immunotherapy treatments encompass immune checkpoint inhibitors, monoclonal antibodies (mAbs), mRNA vaccines, and adoptive cell transfer methods like chimeric antigen receptor (CAR)-T cell therapies. Cancer immunotherapy can be divided into passive and active types depending on how they trigger the immune response. Passive immunotherapy employs agents like lymphocytes, cytokines, or monoclonal antibodies (mAbs) to enhance the body's existing anti-tumor defenses. In contrast, active immunotherapy involves techniques such as vaccination, non-specific immunomodulation, or the targeting of specially designed antigen receptors to cancer cells. Despite the success of various immunotherapy strategies, challenges persist in activating tumor-specific immune responses; these include tumor heterogeneity, suboptimal generation and functioning of tumor-specific CD8 T-cells, a lack of suitable neoantigens, and issues with antigen processing and presentation. Resistance to immune responses is largely tied to T-cell immune checkpoint pathways. Therefore, investigating molecular mechanisms and identifying new immune checkpoints can help mitigate immune evasion. Strategies to enhance immunotherapy effectiveness must focus on improving tumor site accessibility, facilitating T-cell activation and persistence, diminishing immunosuppression, and preventing T-cell depletion. Monoclonal antibodies (MABS), which can be generated by B

lymphocytes or synthetically, bind to specific molecular targets and have demonstrated anti-cancer efficacy in both preclinical and patient studies through the design of humanized mAbs. They are increasingly favored in cancer treatment due to their specificity and reduced cytotoxicity. Over 22 FDA-approved immunotherapeutic drugs are available for oncological conditions, and evidence suggests mAbs can improve patient survival rates. The various anti-cancer mechanisms linked to mAbs include antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), promoting apoptosis, and inhibiting cell proliferation. The hybridoma technology created by Köhler and Milstein in 1975 enabled the production of therapeutic mAbs. This method combines immunized mouse spleen cells capable of antibody production with immortalized cancer B-cell myeloma cells. Although hybridoma-based mAbs exhibit advantages like low aggregation and strong antigen binding, murine mAbs face limitations such as a short half-life and low biological activity. Notably, muromonab-CD3 became the first therapeutic mAb to gain FDA approval in 1985. Recent advancements in mAb development emphasize antibody engineering techniques to create humanized and fully human antibodies, which have lower immunogenicity and improved efficacy compared to murine mAbs. mAbs are used in various capacities in cancer therapy, including as immune checkpoint inhibitors (ICIs), antibody-drug conjugates, and bispecific T-cell engagers, working through mechanisms such as receptor and ligand blocking, CDC, and ADCC. Rituximab, the first FDA-approved chimeric mAb, was authorized in 1997 for treating non-Hodgkin lymphoma. Cancer cells often evade T-cell responses, highlighting the importance of enhancing anti-tumor immunity through immune checkpoint inhibition. Recent insights into T-cell biology have led to emerging therapies targeting tumor immune escape mechanisms. Immune checkpoints help regulate T-cell activation, and several antibodies are being developed to inhibit these checkpoints. PD-1 and CTLA-4 represent key targets in immune checkpoint therapy. Ipilimumab was the first CTLA-4 inhibitor approved in 2011, positively impacting melanoma patient survival. Meanwhile, PD-1 inhibitors, including nivolumab and pembrolizumab, have also emerged as effective options. Other promising immune checkpoints like LAG-3 and TIM-3 are being explored for further therapeutic opportunities. Chimeric Antigen Receptor (CAR)-T cell therapy represents another innovative approach, utilizing genetically modified T-cells to target tumors more effectively, especially in hematological cancers. CAR-T cells are derived from patients' own T-cells, and recent studies are exploring their use against various antigen targets. While CAR-T therapies have been successful, their efficacy is currently limited in solid tumors due to various challenges, including tumor-specific antigens and the microenvironment. Cancer vaccines aim to trigger immune responses against tumor antigens, with preventive and therapeutic applications. Although progress has been made, especially with vaccines for virus-associated cancers, broader applications remain limited due to issues like a lack of specific tumor antigens and avoiding autoimmune reactions. However, mRNA vaccines are emerging as a promising therapeutic strategy, showing potential to induce strong immune responses without integrating into the host genome.

Advanced Cancer

The number of treatment options for advanced cancer has increased dramatically in recent years. These innovations in therapies, such as immunotherapy and targeted treatments, alongside enhancements in traditional options like chemotherapy, radiation, and surgery, aim to improve patient outcomes. Supportive care

therapies also play a crucial role in managing side effects and enhancing quality of life during and following treatment. However, treating advanced cancer can be complex, often leading patients to confront challenging decisions about their care. Some individuals might be diagnosed at an already advanced stage, while others may see their cancer progress despite ongoing treatment. The speed of cancer progression, its type, and how patients respond to therapies can lead to differing experiences regarding symptoms and side effects. Being diagnosed with advanced cancer, or learning that a loved one's condition has worsened, can be overwhelming. If you find yourself in this situation, you might have several pressing questions, such as:

- What should we do next?
- What is the likelihood of responding to another treatment?
- What side effects might I expect from new treatments?
- Can I take a break from treatment?
- What is my life expectancy with advanced cancer?

Every patient's situation is distinct, and it's essential to have discussions with your healthcare provider about the options available. Depending on your specific clinical circumstances, there may be further treatment alternatives for advanced cancer. This article provides insights into:

- The definition of advanced cancer
- Goals of treatment for advanced cancer
- Available treatment options
- Questions to pose to your oncologist
- Locations of advanced cancer treatment centers

If you are curious about treatment options for advanced cancer or seek a second opinion at one of our facilities, please reach out to us via phone or online chat with a team member.

Understanding Advanced Cancer

"Advanced cancer" is a broad term. According to the National Cancer Institute, it refers to cancer that is not expected to be cured or effectively controlled through treatments. This term commonly describes cancers that have progressed beyond earlier stages, may have spread (metastasis), or have recurred after remission. Some patients may not require immediate treatment for an extended time, while others may be diagnosed with stage 3 or 4 cancer initially.

Symptoms of Advanced Cancer

Patients with advanced cancer can exhibit varying symptoms; some may feel relatively well despite the disease's progression while others might experience significant discomfort, impacting their quality of life. The type of cancer plays a significant role in symptom presentation— for instance, individuals with slow-growing non-Hodgkin lymphoma might not require immediate treatment. The patient's physical well-being and emotional coping strategies can be just as critical as clinical indicators.

Goals of Treatment for Advanced Cancer

The treatment objectives for each patient can differ widely. Generally, the aims of therapy may include slowing the disease's progression, alleviating symptoms, and making life more comfortable amidst treatment. As treatments evolve, there are instances where certain cancers can be treated as chronic conditions. For instance, chronic myeloid leukemia is increasingly managed with oral tyrosine kinase inhibitors instead of the previously standard bone marrow transplants. Immunotherapy is showing promise for some patients, providing prolonged disease control and even allowing for treatment pauses without adverse effects on their health. Balancing the goals of symptom management and treatment side effects is essential, and patients retain the right to decide on their treatment paths. Conversations with healthcare providers about potential alternative treatments are vital.

Treatment Options for Advanced Cancer

Multidisciplinary care is often necessary for treating advanced cancer, as patients may benefit from multiple treatment modalities. For instance, a patient with locally advanced breast cancer might undergo chemotherapy to shrink the tumor before surgery, which could allow for a less invasive procedure. Post-surgery, they may require radiation, further chemotherapy, or hormonal therapy. Physicians must evaluate a patient's ability to tolerate different treatment regimens since many individuals may have coexisting health conditions that affect treatment decisions. Your care team will develop a personalized treatment plan tailored to your unique needs. While this overview does not encompass all advanced cancer treatments, it highlights common approaches that aim to manage the disease and improve patient quality of life.

Chemotherapy for Advanced Cancer

Chemotherapy remains a widely used option for advanced cancer, often employed for both symptom relief and disease management. It can be given through infusions, orally, via injections, or topical creams. Some patients may even receive chemotherapy in their homes.

Radiation Therapy for Advanced Cancer

Radiation therapy can serve as a primary treatment or complement other therapies. It may also provide pain relief for patients with advanced cancer, such as those experiencing bone pain from tumors. Advances in technology enable radiation oncologists to deliver targeted radiation, reducing side effects associated with traditional treatments.

Surgery for Advanced Cancer

Surgery may be initially employed after diagnosis or used in later stages, often in conjunction with other treatments to remove tumors or alleviate pain through palliative measures.

Immunotherapy for Advanced Cancer

Immunotherapy harnesses the body's immune system to target cancer cells. This treatment can be particularly effective for certain cancer types, such as advanced lung cancer, where new immunotherapy drugs have significantly improved patient outcomes.

Targeted Therapies for Advanced Cancer

Targeted therapies focus on specific cancer characteristics, like proteins or genetic mutations. These treatments aim to slow the cancer's growth and are often customized based on genetic testing results. Examples include monoclonal antibodies, hormone therapies, and small molecule drugs targeting specific mutations across various cancer types. In conclusion, immunotherapy has made significant strides in cancer treatment, particularly through the development of CAR-T therapies, ICIs, and cancer vaccines. Combining these therapeutic approaches has shown promise in enhancing treatment efficacy. Ongoing research aims to refine and overcome existing challenges, ultimately leading to more effective therapies with higher response rates and fewer side effects for cancer patients. As genomic and molecular therapies evolve, understanding and leveraging molecular tumor profiles will be key to developing effective cancer treatments, potentially aided by artificial intelligence in clinical decision-making processes.

REFERENCES

1. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca. Cancer J. Clin. 71, 209–249 (2021).
2. Steinberg, F. M. & Raso, J. Biotech pharmaceuticals and biotherapy: an overview. J. Pharm. Pharm. Sci. 1, 48–59 (1998).
3. Sun, X. et al. Imatinib induces ferroptosis in gastrointestinal stromal tumors by promoting STUB1-mediated GPX4 ubiquitination. Cell Death Dis. 14, 839 (2023).
4. Tewari, K. S. et al. Bevacizumab for advanced cervical cancer: final overall survival and

adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390, 1654–1663 (2017).

5. Myers, R. M. et al. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T cells in CAR-Naïve and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J. Clin. Oncol. J. Am. Soc. Clin. Oncol. 39, 3044–3055 (2021).
6. Zhang, T. et al. Talimogene Laherparepvec (T-VEC): A review of the recent advances in cancer therapy. J. Clin. Med. 12, 1098 (2023).
7. Lemberg, K. M., Gori, S. S., Tsukamoto, T., Rais, R. & Slusher, B. S. Clinical development of metabolic inhibitors for oncology. J. Clin. Invest. 132, e148550 (2022).
8. D.A. Christian et al. Polymersome carriers: from self-assembly to siRNA and protein therapeutics Eur. J. Pharm. Biopharm.(2009)
9. D. Hanahan Hallmarks of cancer: new dimensions Cancer Discov. (2022)
10. T. Gutschner et al. The hallmarks of cancer: a long non-coding RNA point of view RNA Biol. (2012) R.A. Wang et al.
11. Reasons for cancer metastasis: a holistic perspective Molecular and clinical oncology (2015) S. Quintero-Fabian et al.
12. Role of matrix Metalloproteinases in angiogenesis and cancer Front. Oncol.(2019)
13. C. Tomasetti et al. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention Science (2017)
14. B. Vogelstein et al. Cancer genes and the pathways they control Nat. Med.(2004)
15. Dagogo-Jack et al. Tumour heterogeneity and resistance to cancer therapies Nat. Rev. Clin. Oncol.(2018)
16. C.P. Halsted et al. A historical account of breast cancer surgery: beware of local recurrence but be not radical Future Oncol. (2014)
17. V. Schirrmacher From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment Int. J. Oncol.(2019)
18. U. Anand et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics Genes and Diseases (2022)
19. L. Falzone et al. Evolution of cancer pharmacological treatments at the turn of the third millennium Front. Pharmacol. (2018).

HOW TO CITE: Priyanka Tadkase*, Shital Bhimewar, Pallavi Bawanthade, Fiza Firoz Karvinkar, Dhanashri Chelmelwar, Advancements of Cancer Treatments and Cure, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 2, 962-967. https://doi.org/10.5281/zenodo.14864223